Chemaphor expands companion animal studies program
Tuesday, 12 July 2011 07:25 AM
New funding will support
next round of OxC-beta studies in dogs, cats and horses
Chemaphor
Inc. (TSX Venture: CFR) will expand its companion animal studies program for
OxC-beta to include cats and horses. An additional study will be conducted with
dogs to reinforce the earlier findings that OxC-beta significantly improves
coat quality and shedding and markedly improves mobility and interest in
activities, particularly in older animals.
“The funding from NRC-IRAP will
allow us to expand and accelerate our commercialization program,” says Dr.
Graham Burton, president and co-founder of Chemaphor
Inc. “These new studies will allow us to broaden application to other species, especially cats
and horses.”
The two year term financial support of up to $194,094 of non-dilutive, non-repayable funding will
allow Chemaphor to continue to learn
more about the full extent of the benefits of OxC-beta as a natural health supplement for companion animals and
horses. This includes strengthening, through objective measurement, previous
findings that show OxC-beta
helped improve the condition of dogs
with skin and coat issues. The
studies will also focus on demonstrating the benefit and safety of OxC-beta as a daily health supplement for
companion cats and horses, and will provide further insight into additional therapeutic
applications of OxC-beta.
Chemaphor,
through its commercial subsidiary, Avivagen Animal Health Inc., introduced
OxC-beta into Canadian veterinary clinics in late 2010, in the form of
Oximunol™ Chewables for dogs. Building upon the very positive response of
Canadian pet owners in just six months, Avivagen is now working on establishing
agreements with partners for international distribution of Oximunol™ Chewables.
Avivagen also markets an in-licensed Vet-Stem stem cell treatment. For more
information visit www.avivagen.com or follow
on Twitter @avivagen.
Chemaphor
is listed on the TSX Venture Exchange and trades under the symbol CFR.
###
For more information:
David Hankinson Graham
Burton, PhD
CEO, Chemaphor Inc. President
and Co-Founder, Chemaphor Inc.
Phone: 902-825-9270 Phone:
613-990-0969
[email protected] [email protected]
Investor
Relations: Media Group
Evolution Group Inc. McCormick
Global Communications
Sylvain Archambault Karen
Sample
514-448-4887 / Toll free: 866-703-4887 519-475-6378
[email protected] [email protected]
www.evolutiongrp.com
Forward Looking
Statements
This news release
includes certain forward-looking statements that are based upon current
expectations, which involve risks and uncertainties associated with the
business of Chemaphor Inc. and Avivagen Animal Health Inc. and the environment
in which their respective businesses operate. Any statements contained herein
that are not statements of historical facts may be deemed to be forward-looking,
including those identified by the expressions “will”, "anticipate",
"believe", "plan", "estimate",
"expect", "intend", and similar expressions. The
forward-looking statements reflect the current expectations of Chemaphor Inc.
regarding future results or events. These forward-looking statements are
subject to a number of risks and uncertainties that could cause actual results
or events to differ materially from current expectations. Chemaphor assumes no
obligation to update the forward-looking statements, or to update the reasons
why actual results could differ from those reflected in the forward-looking
statements.
The foregoing is only a
brief summary of the methodology and results of the above referenced study.
The results discussed above are not a guarantee of future product
performance or that any products currently in development will reach the
commercialization stage in the near term or at all. Commercialization of
any product may require additional studies and/or satisfaction of regulatory
and other requirements, some of which may be outside of the control of
Chemaphor Inc. and Avivagen Animal Health Inc.
Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term is defined
in the policies of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
